Perceptive Advisors Llc - Oct 11, 2022 Form 4 Insider Report for ALBIREO PHARMA, INC. (ALBO)

Role
10%+ Owner
Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol
ALBO
Transactions as of
Oct 11, 2022
Transactions value $
-$9,505,547
Form type
4
Date filed
10/13/2022, 07:37 PM
Previous filing
Aug 22, 2022
Next filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale -$2.33M -100K -4.25% $23.23 2.26M Oct 11, 2022 See Footnote F1, F8
transaction ALBO Common Stock Sale -$926K -38.3K -1.7% $24.18 2.22M Oct 11, 2022 See Footnote F2, F8
transaction ALBO Common Stock Sale -$134K -5.42K -0.24% $24.78 2.22M Oct 11, 2022 See Footnote F3, F8
transaction ALBO Common Stock Sale -$2M -90K -4.06% $22.26 2.13M Oct 12, 2022 See Footnote F4, F8
transaction ALBO Common Stock Sale -$168K -7.24K -0.34% $23.23 2.12M Oct 12, 2022 See Footnote F5, F8
transaction ALBO Common Stock Sale -$3.93M -179K -8.44% $22.01 1.94M Oct 13, 2022 See Footnote F6, F8
transaction ALBO Common Stock Sale -$9.25K -406 -0.02% $22.79 1.94M Oct 13, 2022 See Footnote F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Perceptive Advisors Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.75 to $23.715 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.74 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.87 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22 to $22.995 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23 to $23.965 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.74 to $22.73 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.74 to $22.79 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F8 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.